Is Connect Biopharma Holdings Limited (CNTB) a Buy, Sell, or Hold?
NASDAQ : CNTB
Connect Biopharma Holdings Limited
$2.14 USD
-$0.06 (-2.73%)
- Volume
- 327.69K
- Average Volume
- 370.92K
- Market Capitalization
- $134.74M
- P/E Ratio
- -4.28
- Dividend Yield
- 0.00%
- Price Target
- $7.00
- Year High
- $3.82
- Year Low
- $1.23
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.74
Company Overview
NASDAQ
Barry D. Quart
Biotechnology
Healthcare
CNTB
64
US
USD
Liquidity Metrics
0.02
3.74
3.74
2.82
0.00
Sales & Valuation
$64000
2807.14
2.84
-5.58
-0.43
Profitability
-$1
-$55.48M
-58350.00%
-58179.17%
-49.43%
-49.95%
P/E Metrics
-4.28
0.03
0.03
Analyst Price Target & Rating
$7.00
$8.00
$4.00
2/5
5 Analysts
-69.43%
Financial Health Scores
-4.15
1/9
$37.32M
$56.08M
$14.1M
-$21.83M
Key Metrics (TTM)
$97.09M
2022.66
-3.52
3.74
-49.43%
-67.67%
-23.51%
-17.93%
1224 days
Company Executives
| Name | Title |
|---|---|
| Barry D. Quart | Chief Executive Officer & Director |
| Jeff Cohn | General Counsel & Corporate Secretary |
| Lei Sun | Vice President of Biologics & Head of CMC |
| Sean T. Ristine | Vice President of Human Resources |
| Lisa Peraza | Senior Vice President of Finance |
| Srikanth Pendyala | Senior Vice President of Clinical Development(Consultant) |
| David L. Szekeres | President |
| Kimberly J. Manhard | Executive Vice President & Chief Development Officer |
Poll Results
No votes yet today — be the first to share your view!
About Connect Biopharma Holdings Limited (NASDAQ:CNTB) Stock
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II d ... evelopment for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent
2026-07-23 02:15:39
CNTB is developing rademikibart, a drug with a similar mechanism of action to SNY/REGN's blockbuster Dupixent. The company is approaching a readout from two trials, Seabreeze STAT Asthma and Seabreeze STAT COPD, which have the potential to show a benefit of rademikibart for acute exacerbations. CNTB raised net proceeds of $18.6M in Q1'26 with a private placement, with cash of $46M at the end of that quarter.
2026-06-17 09:00:00
– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway into 2H 2027 – SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced the completion of enrollment in its Phase 2 Seabreeze STAT Asthma study evaluating the safety and efficacy of rademikibart, the Company's next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, as an adjunct to standard of care for acute exacerbations in participants with asthma and type 2 inflammation. “Completion of enrollment in our Seabreeze STAT Asthma study marks another significant step in our mission to deliver the first biologic to treat patients suffering from an acute exacerbation of asthma,” said Barry Quart, Pharm.D.
Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026
2026-05-22 00:05:16
Connect Biopharma NASDAQ: CNTB Chief Executive Officer Barry Quart said the company's rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits mid-2026 data from its SEABREEZE study.
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
2026-05-12 16:05:00
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that Company management will participate in a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at 9:30 a.m. ET.
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-12 09:00:00
– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned based on independent DMC review of pre-specified interim analysis –
Connect Biopharma: New Market Opportunity In The Emergency Setting
2026-04-29 10:08:58
Connect Biopharma Holdings is rated a risky Buy, with high upside potential hinging on mid-2026 Phase 2 trial results for rademikibart. Rademikibart has shown superior efficacy and safety to Dupixent in China Phase 3 trials, with commercialization led by Simcere and low-double-digit royalties to CNTB. CNTB is targeting the emergency asthma and COPD settings in the US, a market with no approved biologics, and expects pivotal Phase 2 data in mid-2026.
Frequently Asked Questions
-
What is the current Connect Biopharma Holdings Limited (CNTB) stock price?
-
Connect Biopharma Holdings Limited(NASDAQ:CNTB) stock price is $2.14 in the last trading session. During the trading session, CNTB stock reached the peak price of $3.82 while $1.23 was the lowest point it dropped to. The percentage change in CNTB stock occurred in the recent session was --2.73% while the dollar amount for the price change in CNTB stock was -$0.06.
-
CNTB's industry and sector of operation?
-
The NASDAQ listed CNTB is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CNTB?
-
Barry D. Quart | Chief Executive Officer & Director
Jeff Cohn | General Counsel & Corporate Secretary
Lei Sun | Vice President of Biologics & Head of CMC
Sean T. Ristine | Vice President of Human Resources
Lisa Peraza | Senior Vice President of Finance -
How many employees does CNTB have?
-
Number of CNTB employees currently stands at 64. CNTB operates from 3580 Carmel Mountain Road, San Diego, CA 215400, US.
-
Link for CNTB official website?
-
Official Website of CNTB is: https://www.connectbiopharm.com
-
How do I contact CNTB?
-
CNTB could be contacted at phone #86 512 5357 7866 and can also be accessed through its website. CNTB operates from 3580 Carmel Mountain Road, San Diego, CA 215400, US.
-
How many shares of CNTB are traded daily?
-
The average number of CNTB shares traded daily for last 3 months was 370.92K.
-
What is the market cap of CNTB currently?
-
The market value of CNTB currently stands at $134.74M with its latest stock price at $2.14